BioMarin Pharmaceuticals
BMRN
482 hedge funds and large institutions have $15.3B invested in BioMarin Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 57 funds opening new positions, 175 increasing their positions, 173 reducing their positions, and 54 closing their positions.
43% more funds holding in top 10
Funds holding in top 10: 7 → 10 (+3)
6% more first-time investments, than exits
New positions opened: 57 | Existing positions closed: 54
1% more repeat investments, than reductions
Existing positions increased: 175 | Existing positions reduced: 173
0.56% less ownership
Funds ownership: 100.09% → 99.53% (-0.56%)
1% less funds holding
Funds holding: 485 → 482 (-3)
4% less capital invested
Capital invested by funds: $15.9B → $15.3B (-$600M)
37% less call options, than puts
Call options by funds: $106M | Put options by funds: $168M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
+$258M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$178M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
+$167M |
| 4 |
YCMGA
York Capital Management Global Advisors
New York
|
+$95.5M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
+$85.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$254M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$217M |
| 3 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$151M |
| 4 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$80.8M |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$71.1M |
BMRN Hedge Fund Activity: Q2 2019 in Review
482 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q2 2019, worth a combined $15.3B — down 3.8% from $15.9B a quarter earlier.
Buyers outnumbered sellers: 57 funds opened new BMRN positions and 54 closed out — a net gain of 3 holders — while 175 added to existing stakes and 173 trimmed.
The largest buyer was Nuveen, opening a new position worth an estimated $258M. The largest seller was Jennison Associates, cutting an estimated $254M.
- 482 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q2 2019, down from 485 in Q1 2019.
- Funds reported $15.3B of BioMarin Pharmaceuticals stock for Q2 2019, down 3.8% quarter-over-quarter.
- 57 funds opened new BioMarin Pharmaceuticals positions in Q2 2019 and 54 closed out, a net change of +3 holders.
- The largest BioMarin Pharmaceuticals buyer in Q2 2019 was Nuveen, an estimated $258M added.
- The largest BioMarin Pharmaceuticals seller in Q2 2019 was Jennison Associates, an estimated $254M sold.
Based on aggregated 13F filings for Q2 2019.